A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306) (Q34269566)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Monika E Hegi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Myrna Rosenfeld

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

6

Glenn Lesser

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Thomas Mikkelsen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Xiaubu Ye

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Tracy Batchelor

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

David Peereboom

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Jeff Olsen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Steve Brem

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Joy D Fisher

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Stuart A Grossman

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System Consortium

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

English

0 references

publication date

19 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

5601-5607

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

29 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423527

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423527

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423527

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423527

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423527

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423527

Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423527

MGMT gene silencing and benefit from temozolomide in glioblastoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423527

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423527

Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423527

Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423527

alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.

6 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.27585

Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.27585

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.27585

Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3423527

28 October 2018

Identifiers

DOI

10.1002/CNCR.27585

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

PubMed publication ID

22517399

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517399%20AND%20SRC:MED&resulttype=core&format=json